MedTrace Logo

ADC-1013 First-in-Human Study

NCT02379741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-03-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or intravenously (as repeated doses directly into a vein) in patients with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

ADC-1013

Agonistic human monoclonal IgG1 anti-CD40 antibody

Sponsors & Collaborators

  • Alligator Bioscience AB

    lead INDUSTRY

Principal Investigators

  • Per Norlén, MD, PhD · Alligator Biosciene AB, Sweden

  • Dorte Nielsen, MD, PhD · Department of Oncology Herlev Hospital, Denmark

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-03-08
Completion
2017-03-08

Countries

  • Denmark
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02379741 on ClinicalTrials.gov